Company Overview of Angiogenix, Inc.
Angiogenix, Inc., a biopharmaceutical company, develops therapeutic solutions for chronic vascular disease. Its products include ACCLAIM, a treatment for chronic ischemia; ANGX-1039, a peripheral vascular disease drug therapy for peripheral blood flow; ANGX-3227, a treatment for sickle cell disease; and Vasotrophin, a product for the generation of blood vessels. The company serves cardiovascular disease, peripheral vascular disease, and sickle cell disease markets. Angiogenix, Inc. was founded in 1997 and is headquartered in Burlingame, California.
500 Airport Boulevard
Burlingame, CA 94010
Founded in 1997
Key Executives for Angiogenix, Inc.
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
To contact Angiogenix, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.